Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body…
Articles by Margarida Maia, PhD
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as…
Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission…
Bizengri (zenocutuzumab-zbco) is now approved in the U.S. as the first treatment for advanced pancreatic cancer and non-small cell…
Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based…
Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than…
For about one-third of women with a neuroendocrine tumor — or an abnormal mass of tissue that forms from hormone-releasing…
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of…
AbbVie’s Elahere (mirvetuximab soravtansine) has been approved in the European Union to treat adults with advanced ovarian, fallopian tube,…
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination…